Palisade Bio Doses First Patient In Its ASCENTRA-UC Phase 2b Clinical Trial Evaluating PALI-2108 In ~204 Patients With Moderately To Severely Active Ulcerative Colitis; 12-Week Topline Results Expected In Q4 2027
Benzinga Newsdesk 3 days ago
News
PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory activity with the potential to improve tolerability29 of 30 planned U.S. sites
PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory activity with the potential to improve tolerability
29 of 30 planned U.S. sites already activated
Global expansion progressing toward ~115 total sites, with CTA clearance in Canada and submissions under review in Europe and other international countries